STAR-001 and spironolactone for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called STAR-001 combined with spironolactone for people whose glioblastoma (a type of brain cancer) has come back after initial treatment. The goal is to see if this combination is safe and if it can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of supratentorial glioblastoma (GBM) that has returned or progressed after first treatment.
- You can have had only one prior treatment for your GBM (like temozolomide with radiation, possibly with an experimental agent or tumor-treating fields).
- You must have a tumor that can be seen on MRI and is measurable per RANO criteria.
- You must be between 18 and 69 years old.
- Your overall health must be good enough (Karnofsky score of 70% or higher).
- If you are on steroids (like dexamethasone), the dose must be stable or decreasing for at least 7 days before the MRI, and it must be less than 4 mg per day (unless you are having surgery).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
This trial tests a virus-based treatment for glioblastoma that has come back after standard therapies. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a new drug called ACT001 for people with recurrent glioblastoma (a type of brain cancer) whose tumors have a specific marker (STAT3-high). The drug targets that marker to try to stop the tumor from growing.
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
This trial tests a new treatment called STARLITE for people with fast-growing brain tumors (high-grade gliomas) that cannot be safely removed with surgery. The treatment uses a laser to destroy the tumor from the inside. It may be a good option if you haven't had any prior treatment for this tumor.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.